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Pandemic (H1N1) 
2009 and Seasonal 
Inﬂ  uenza A (H3N2) 
in Children’s 
Hospital, Australia
To the Editor: We read with 
interest the report by Carcione et al. of 
clinical features of pandemic inﬂ  uenza 
A (H1N1) 2009 and comparison of 
these with 2009 seasonal inﬂ  uenza 
infection in a population-based 
study from Western Australia (1). 
Here we share our experience of 
hospitalizations for inﬂ   uenza in a 
tertiary care children’s hospital in 
Sydney, New South Wales, Australia, 
during the 3 peak inﬂ  uenza seasons of 
the last decade.
During the 2009 Southern 
Hemisphere single inﬂ  uenza  wave 
(June–September), we prospectively 
studied every child <15 years of age 
who was hospitalized with laboratory-
conﬁ  rmed inﬂ  uenza (74% had proven 
pandemic [H1N1] 2009) in Children’s 
Hospital at Westmead (CHW), Sydney, 
as part of a collaboration between the 
National Centre for Immunisation 
Research and Surveillance and the 
Australian Paediatric Surveillance 
Unit. The study was approved by the 
Human Research Ethics Committee at 
CHW and supported by the state (New 
South Wales) health department. Data 
from hospitalizations for seasonal 
inﬂ  uenza at CHW in 2003 and 2007 
(previous peaks in the last decade) 
were analyzed by using our previous 
studies and medical records (2–4). To 
compare pneumonia rates, we used 
the same case deﬁ  nitions in 2007 and 
2009 (radiologic changes consistent 
with pneumonia). Proportions were 
compared by using the χ2 statistic.
In 2009, the numbers of children 
with laboratory-conﬁ  rmed  inﬂ  uenza 
admitted to the hospital and to the 
pediatric intensive care unit (PICU) at 
CHW (226 and 22, respectively) were 
nearly double those admitted in 2007 
(122 and 12) but similar to the number 
in 2003 (257 and 22). The proportion 
of case-patients admitted to the PICU, 
the length of hospital stay, and the 
length of PICU stay were similar in 
2003, 2007, and 2009. 
In 2009, among the 226 inﬂ  uenza-
associated hospitalizations, 167 
(74%) were for pandemic (H1N1) 
2009 infection; in 2007, 119 of 122 
inﬂ  uenza-associated  hospitalizations 
were for seasonal inﬂ  uenza A (H3N2) 
infection (Table). During the 2009 
pandemic wave, of all children 
admitted with laboratory-conﬁ  rmed 
inﬂ  uenza, the proportion hospitalized 
with pandemic (H1N1) 2009 who 
were <6 months of age was similar to 
the proportion of children <6 months 
of age hospitalized with seasonal 
(H3N2) inﬂ  uenza in 2007 (21 [13%] of 
167 and 21 [18%] of 119, respectively; 
p = 0.31). The proportions of those >5 
years of age were signiﬁ  cantly higher 
(61 [37%] and 15 [13%]; p = 0.0001). 
However, the proportion of those 
>5 years of age admitted to PICU in 
2009 was less than in 2007 (10 [16%] 
of 61 vs. 3 [20%] of 15; p = 0.71). 
Similar percentages of children with 
preexisting conditions were admitted 
in 2009 and 2007 (47% and 49%, 
respectively). However, pneumonia 
was a more frequent complication in 
2009 than in 2007 (42 [25%] of 167 
vs. 15 [13%] of 119; p = 0.01). In 
2009, the proportion of children with 
pandemic (H1N1) 2009 who needed 
mechanical ventilation (7 [4%] of 167) 
was similar to the proportion in 2007 
who had seasonal inﬂ  uenza (H3N2) (6 
[5%] of 119; p = 0.77). Furthermore, 
no child at CHW in 2007 or in 2009 
received extracorporeal membrane 
oxygenation.
Vomiting occurred much more 
frequently in 2009 than in 2007 (59 
[35%] of 167 vs. 16  [13%] of 119; p 
= 0.0001). In 2009, of 62 children who 
did not exhibit vomiting when ﬁ  rst 
examined, and who were subsequently 
treated with antiviral drugs, only 1 had 
vomiting develop in the hospital. This 
condition resolved within hours, and 
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the 5-day course of antiviral treatment 
was completed. Chart review 
showed that in no child did antiviral 
treatment exacerbate vomiting, and 
no children required antiemetic 
treatment or intravenous rehydration. 
These data suggest that oseltamivir 
was uncommonly associated with 
vomiting in hospitalized children.
In macaque monkeys, pandemic 
(H1N1) 2009 virus is more pathogenic 
than seasonal inﬂ  uenza  A  (H1N1), 
particularly affecting the lungs (5). 
The signiﬁ   cantly higher proportion 
(and number) of pneumonia patients 
at CHW in 2009 than in 2007 (Table) 
seems to provide additional evidence 
of the pathogenecity of pandemic 
(H1N1) 2009 virus. However, the 
number of children with laboratory-
conﬁ  rmed  inﬂ   uenza admitted to the 
hospital was similar in 2009 and 2003. 
Given that the sensitivity of inﬂ  uenza 
laboratory tests has improved over 
time (e.g., greater use of nucleic acid 
tests), these data suggest that the 
incidence of hospitalization during 
the 2009 pandemic was not greater 
than the incidence during the 2003 
inﬂ  uenza season.
Although pneumonia appeared 
more likely to be diagnosed in 
hospitalized children in 2009 than 
in 2007, we observed no increase 
in the risk for serious outcomes 
(PICU admission or ventilation rate, 
length of admission, or death) in 
children hospitalized with pandemic 
(H1N1) 2009 infection than in 
children hospitalized with seasonal 
inﬂ  uenza (H3N2) during the 2 peak 
years studied. The 2009 pandemic 
had an effect on children’s services 
that was comparable to the busiest 
interpandemic inﬂ  uenza season of the 
previous decade. The large number 
of admissions and complications, 
including in children with no existing 
medical condition, supports the need 
for universal inﬂ  uenza vaccination.
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Table. Comparison of influenza-related hospitalizations, Children’s Hospital at Westmead, Sydney, Australia, 2003, 2007, and 2009 
influenza seasons* 
Characteristics†
2009, pandemic (H1N1) 2009, 
no. (%), n = 167 
Seasonal influenza A (H3N2), no. (%) 
2007, n = 119  2003, n = 257‡ 
PICU admissions  18 (10.8)  12 (10.1)  22 (8.6) 
Fatal cases (within 30 d of hospital admission)  0 0 3 (1.2) 
Ventilated 7 (4.2)  6 (5.0)  14 (5.4) 
Treated with antiviral drug§  92 (55.1)  16 (13.4)  0
Symptoms 
 Vomiting§  59 (35.3)  16 (13.4)  NA
 Diarrhea  21 (12.6)  8 (6.7)  NA
 Seizure  11 (6.6)  7 (5.9)  NA
Complications
 Any  complication  65 (38.9)  35 (29.4)  NA
 Pneumonia¶  42 (25.1)  15 (12.6)  NA
 Encephalopathy  5 (3.0)  2 (1.7)  NA
Preexisting condition  78 (46.7)  60 (50.4)  NA
*PICU, pediatric intensive care unit; NA, not available. 
†Length of hospital stay, mean (range), d: pandemic (H1N1) 2009, 5.9 (1–107); seasonal influenza in 2007, 4.1 (1–50); seasonal influenza in 2003, 4 (1–
28). Length of PICU stay, mean (range), d: pandemic (H1N1) 2009, 3.7 (1–30); seasonal influenza in 2007, 4.3 (1–25); seasonal influenza in 2003, 3.3 
(0.6–11.4) Data for length of PICU stay in 2003 exclude 3 deaths; 1.3, 2.3, and 4.8 d after PICU admission (2.8 d mean PICU stay). 
‡Only isolates from the 22 PICU case-patients were subtyped; all were H3N2. 
§p = 0.0001. 
¶p = 0.0104. LETTERS
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Global Health 
Security in an Era 
of Global Health 
Threats
To the Editor: Global health 
security is the protection of the 
health of persons and societies 
worldwide. It includes access to 
medicines, vaccines, and health care, 
as well as reductions in collective 
vulnerabilities to global public health 
events that have the potential to 
spread across borders. For example, 
transboundary zoonotic diseases such 
as avian inﬂ  uenza (H5N1) infections 
affect animals and humans, thereby 
threatening health security worldwide 
because of their high death rates 
(≈60% in humans) (1).
During the past 15 years, fairly 
standardized responses to threats 
have been implemented around the 
globe. Some of these responses have 
been against severe acute respiratory 
syndrome and avian inﬂ  uenza 
(H5N1), which have been overseen by 
a well-resourced international health 
system (2).
These global health threats 
have raised the highest levels of 
political and social concern. This 
concern has provoked governments 
and international agencies to 
address health threats through a 
security rationale, which emphasizes 
the themes of national security, 
biosecurity, and human security. 
This amalgamation of health issues 
and security concerns has produced 
a notion of health security, which 
is dominated by technical medical 
approaches and pharmaceutical 
interventions. These approaches and 
interventions have already begun to 
shape the way international health 
policy is formulated (3).
A global vision of health security 
is very much part of contemporary 
rhetoric. However, this vision 
lacks the drive and speed needed 
to make proposals materialize and 
operationalize ideas in the geographic 
areas where they are most desperately 
needed. Small beneﬁ   ts accrue to 
members of vulnerable populations 
who, in fact, are those most likely 
to be affected by epidemic diseases. 
A public health security design that 
impinges on a global approach runs the 
risk of neglecting cultural, economic, 
ecologic, and social conditions on 
the ground. Regional approaches that 
address hazards and threats may be 
more inclusive of context-speciﬁ  c 
conditions (4).
Global public health threats 
related to infectious pathogens of 
animal origin are expected to rise. To 
address these threats, several experts 
and strategists suggest the initiation 
of a worldwide early-alerting and 
-reporting mechanism. Aggregation 
of disease threats through an event-
focused Web-based platform could 
enable this mechanism. This timely 
gathering of disease intelligence can 
inform policymakers about the nature 
of risks. Disease maps can display 
details needed to design tailored 
policies and control measures to tackle 
diseases according to their speciﬁ  cs 
(5).
Leading scientists and researchers 
continue to try to understand the global 
temporal and spatial patterns of animal 
diseases. This understanding is gained 
through an array of instruments, 
ranging from the use of satellite 
images to cutting-edge molecular 
technologies. The momentum so far 
has created an open forum for decision- 
makers to collaborate with the leading 
international agencies to advocate 
for surveillance, identiﬁ  cation,  and 
control of zoonotic diseases to uphold 
global public health security (6).
However, global initiatives suffer 
from the free-rider problem and from 
moral hazards. Some low-income 
countries with weak governance have 
alerted the international community 
about their fragile health care systems 
to capture a nontrivial portion 
of funds that seldom reach their 
intended destinations. These resource 
allocations to developing countries 
foster aid dependence (7).
The international technical 
agencies tasked with upholding 
animal and human health should 
remain at the forefront of identifying 
and addressing evolving threats. 
This process will demand continuous 
ﬂ  exibility, agility, and a coordinated 
international effort. Attaining goals of 
mitigating threats and reducing risks 
posed by the emergence of zoonoses 
requires close collaborations with 
national health authorities and local 
governments. The large investments 
planned to improve foresight and 
prevention might or might not work. If 
they do not work, apportioning blame 
to countries or regions for disease 
ﬂ  are-ups can result in social, political, 
cultural, and economic consequences 
that in the past have turned out to be 
unjustiﬁ   ed, unfair, and ultimately 
detrimental (8).
Clearly, global health threats can 
be reduced only by the concerted 
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